Investigational drug for relapsed b-cell lymphoma or chronic lymphocytic leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational drug (QLS2313) for people with certain blood cancers that have returned or stopped responding to treatment. The drug is given as an injection and may help shrink or control the cancer. This is a phase 1 trial, so the main goal is to find the best dose and see how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell lymphoma or chronic lymphocytic leukemia that has returned or no longer responds to standard treatment.
- You have measurable disease (doctors can track it with tests or scans).
- You have adequate organ function (your liver, kidneys, etc. work well enough).
- You are physically active (able to do light work or be up and about).
- You have not had a prior treatment with a specific type of antibody called a CD79b/CD3/CD20 trispecific antibody.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called QLS5132 for people with advanced solid tumors (cancers that start in organs or tissues). The drug targets a protein called CLDN6 on some cancer cells and might help stop the tumor from growing.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new injectable treatment (called JY231) for people whose B-cell lymphoma has come back or did not respond to standard treatments. The treatment targets a specific marker on cancer cells (CD19) and may help when other options have not worked.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
This trial tests a new immune cell treatment for adults with a type of blood cancer (B-cell lymphoma) that has come back or not improved after standard treatments. The therapy uses specially engineered immune cells to target and destroy cancer cells.
Hear when a new Relapsed/Refractory Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.